Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03879694 · ClinicalTrials.gov registry record · Phase 1
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03879694 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT03879694, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.
Interventions
- BIOLOGICAL Sargramostim
- DRUG Octreotide Acetate
- BIOLOGICAL Incomplete Freund's Adjuvant
- BIOLOGICAL SVN53-67/M57-KLH Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03879694
The ClinicalTrials.gov registry entry for NCT03879694 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sargramostim is the first listed.
NCT03879694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03879694 about?
NCT03879694 is a clinical study titled "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors". This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The ...
What is the current status of trial NCT03879694?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-06-17. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT03879694?
The interventions under investigation include: Sargramostim (BIOLOGICAL), Octreotide Acetate (DRUG), Incomplete Freund's Adjuvant (BIOLOGICAL), SVN53-67/M57-KLH Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03879694?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.